{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:44:40Z","timestamp":1793357080666,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Primary Research and Development Plan of Zhejiang Province","award":["2020C03034"],"award-info":[{"award-number":["2020C03034"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-024-03912-4","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T05:20:51Z","timestamp":1735017651000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Luying","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaomin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"issue":"1","key":"3912_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1053\/j.ajkd.2010.01.008","volume":"56","author":"RJ Glassock","year":"2010","unstructured":"Glassock RJ. The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis Off J Natl Kidney Found. 2010;56(1):157\u201367.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"3912_CR2","doi-asserted-by":"crossref","unstructured":"Yj C, Mh MWJWZC. Z. The characters of antibodies against PLA2R in healthy individuals and in the patient with PLA2R associated membranous nephropathy. Eur J Med Res [Internet]. 2023 Mar 20 [cited 2024 Feb 4];28(1). https:\/\/pubmed.ncbi.nlm.nih.gov\/36935517\/","DOI":"10.1186\/s40001-023-01110-w"},{"issue":"1","key":"3912_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck LH, Bonegio RGB, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"3912_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1681\/ASN.2016070776","volume":"28","author":"AS De Vriese","year":"2017","unstructured":"De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC. A Proposal for a Serology-Based Approach to Membranous Nephropathy. J Am Soc Nephrol JASN. 2017;28(2):421\u201330.","journal-title":"J Am Soc Nephrol JASN"},{"key":"3912_CR5","doi-asserted-by":"publisher","first-page":"593288","DOI":"10.3389\/fimmu.2021.593288","volume":"12","author":"V Tesar","year":"2021","unstructured":"Tesar V, Hruskova Z. Autoantibodies in the Diagnosis, Monitoring, and Treatment of Membranous Nephropathy. Front Immunol. 2021;12:593288.","journal-title":"Front Immunol"},{"issue":"6","key":"3912_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","volume":"12","author":"WG Couser","year":"2017","unstructured":"Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol CJASN. 2017;12(6):983\u201397.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"5","key":"3912_CR7","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1046\/j.1523-1755.2001.0590051983.x","volume":"59","author":"DC Cattran","year":"2001","unstructured":"Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int. 2001;59(5):1983\u201394.","journal-title":"Kidney Int"},{"issue":"4S","key":"3912_CR8","first-page":"S1","volume":"100","author":"Kidney Disease","year":"2021","unstructured":"Kidney Disease. Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1\u2013276.","journal-title":"Kidney Int"},{"issue":"2","key":"3912_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40265-021-01656-1","volume":"82","author":"J Rojas-Rivera","year":"2022","unstructured":"Rojas-Rivera J, Fervenza FC, Ortiz A. Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy. Drugs. 2022;82(2):109\u201332.","journal-title":"Drugs"},{"key":"3912_CR10","doi-asserted-by":"publisher","first-page":"958136","DOI":"10.3389\/fphar.2022.958136","volume":"13","author":"A Perna","year":"2022","unstructured":"Perna A, Ruggiero B, Podest\u00e0 MA, Perico L, Orisio S, Debiec H, et al. Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome. Front Pharmacol. 2022;13:958136.","journal-title":"Front Pharmacol"},{"issue":"6","key":"3912_CR11","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1093\/ckj\/sfw091","volume":"9","author":"M Fiorentino","year":"2016","unstructured":"Fiorentino M, Tondolo F, Bruno F, Infante B, Grandaliano G, Gesualdo L, et al. Treatment with rituximab in idiopathic membranous nephropathy. Clin Kidney J. 2016;9(6):788\u201393.","journal-title":"Clin Kidney J"},{"issue":"6","key":"3912_CR12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1440-1797.2007.00822.x","volume":"12","author":"TM Chan","year":"2007","unstructured":"Chan TM, Lin AW, Tang SC, Qian JQ, Lam MF, Ho YW, et al. Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. Nephrology. 2007;12(6):576\u201381.","journal-title":"Nephrology"},{"issue":"2","key":"3912_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1037\/a0027127","volume":"17","author":"SI Vrieze","year":"2012","unstructured":"Vrieze SI. Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Psychol Methods. 2012;17(2):228\u201343.","journal-title":"Psychol Methods"},{"issue":"1","key":"3912_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","volume":"381","author":"FC Fervenza","year":"2019","unstructured":"Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019;381(1):36\u201346.","journal-title":"N Engl J Med"},{"issue":"4","key":"3912_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","volume":"32","author":"F Scolari","year":"2021","unstructured":"Scolari F, Delbarba E, Santoro D, Gesualdo L, Pani A, Dallera N, et al. Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial. J Am Soc Nephrol JASN. 2021;32(4):972\u201382.","journal-title":"J Am Soc Nephrol JASN"},{"issue":"8","key":"3912_CR16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2215\/CJN.11791018","volume":"14","author":"B Seitz-Polski","year":"2019","unstructured":"Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, et al. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy. Clin J Am Soc Nephrol CJASN. 2019;14(8):1173\u201382.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"5","key":"3912_CR17","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1093\/ndt\/gfh036","volume":"19","author":"PWG du Buf-Vereijken","year":"2004","unstructured":"du Buf-Vereijken PWG, Branten AJW, Wetzels JFM, for the Membranous Nephropathy Study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transpl. 2004;19(5):1142\u20138.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"3912_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1046\/j.1523-1755.2002.00124.x","volume":"61","author":"A Torres","year":"2002","unstructured":"Torres A, Dom\u00ednguez-Gil B, Carre\u00f1o A, Hern\u00e1ndez E, Morales E, Segura J, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int. 2002;61(1):219\u201327.","journal-title":"Kidney Int"},{"issue":"4","key":"3912_CR19","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","volume":"99","author":"G Fern\u00e1ndez-Ju\u00e1rez","year":"2021","unstructured":"Fern\u00e1ndez-Ju\u00e1rez G, Rojas-Rivera J, van de Logt AE, Justino J, Sevillano A, Caravaca-Font\u00e1n F, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986\u201398.","journal-title":"Kidney Int"},{"issue":"9","key":"3912_CR20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","volume":"71","author":"M Praga","year":"2007","unstructured":"Praga M, Barrio V, Ju\u00e1rez GF, Lu\u00f1o J. Grupo Espa\u00f1ol de Estudio de la Nefropat\u00eda Membranosa. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007;71(9):924\u201330.","journal-title":"Kidney Int"},{"issue":"5","key":"3912_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s10157-013-0925-2","volume":"18","author":"T Saito","year":"2014","unstructured":"Saito T, Iwano M, Matsumoto K, Mitarai T, Yokoyama H, Yorioka N, et al. Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial. Clin Exp Nephrol. 2014;18(5):784\u201394.","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"3912_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/0886022X.2017.1325371","volume":"39","author":"Q Liang","year":"2017","unstructured":"Liang Q, Li H, Xie X, Qu F, Li X, Chen J. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy. Ren Fail. 2017;39(1):512\u20138.","journal-title":"Ren Fail"},{"key":"3912_CR23","doi-asserted-by":"publisher","first-page":"107376","DOI":"10.1016\/j.intimp.2021.107376","volume":"94","author":"P Dai","year":"2021","unstructured":"Dai P, Xie W, Yu X, Sun J, Wang S, Kawuki J. Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis. Int Immunopharmacol. 2021;94:107376.","journal-title":"Int Immunopharmacol"},{"issue":"25","key":"3912_CR24","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1056\/NEJMoa067411","volume":"357","author":"H Ekberg","year":"2007","unstructured":"Ekberg H, Tedesco-Silva H, Demirbas A, V\u00edtko \u0160, Nashan B, G\u00fcrkan A, et al. Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation. N Engl J Med. 2007;357(25):2562\u201375.","journal-title":"N Engl J Med"},{"issue":"2","key":"3912_CR25","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2215\/CJN.04800908","volume":"4","author":"M Naesens","year":"2009","unstructured":"Naesens M, Kuypers DRJ, Sarwal M. Calcineurin Inhibitor Nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"3912_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12882-016-0427-z","volume":"18","author":"HZ Qin","year":"2017","unstructured":"Qin HZ, Liu L, Liang SS, Shi JS, Zheng CX, Hou Q, et al. Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients. BMC Nephrol. 2017;18(1):2.","journal-title":"BMC Nephrol"},{"issue":"4","key":"3912_CR27","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","volume":"78","author":"BJ Nankivell","year":"2004","unstructured":"Nankivell BJ, Borrows RJ, Fung CLS, O\u2019Connell PJ, Chapman JR, Allen RDM. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78(4):557\u201365.","journal-title":"Transplantation"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03912-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-024-03912-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-024-03912-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T06:03:26Z","timestamp":1735020206000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-024-03912-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3912"],"URL":"https:\/\/doi.org\/10.1186\/s12882-024-03912-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3963185\/v1","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"17 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study passed an ethical review by the Institutional Review Board of the First Affiliated Hospital, Zhejiang University School of Medicine (Ref no. 2020571). All subject were explained the significance and purpose of the study, and signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"473"}}